Drugs / HT-4253
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06537817 | Sep 2024 → May 2025 | — | Halia Therapeutics, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07399171 Comparator | Apr 2026 → May 2027 expected | Alzheimer disease | Halia Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HT-4253 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06537817 ↗ |
| Route | Oral | “administered orally” NCT06537817 ↗ |